WO2017007271A1 - Aptamer-coated microneedle-based diagnostic skin patch - Google Patents
Aptamer-coated microneedle-based diagnostic skin patch Download PDFInfo
- Publication number
- WO2017007271A1 WO2017007271A1 PCT/KR2016/007410 KR2016007410W WO2017007271A1 WO 2017007271 A1 WO2017007271 A1 WO 2017007271A1 KR 2016007410 W KR2016007410 W KR 2016007410W WO 2017007271 A1 WO2017007271 A1 WO 2017007271A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aptamer
- microneedle
- patch
- skin
- coated
- Prior art date
Links
- 108091023037 Aptamer Proteins 0.000 title claims abstract description 45
- 239000007933 dermal patch Substances 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000004417 polycarbonate Substances 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 11
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 claims description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 7
- 229920000515 polycarbonate Polymers 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000003700 epoxy group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims 1
- 229910000077 silane Inorganic materials 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 21
- 239000000126 substance Substances 0.000 description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 5
- -1 polydimethylsiloxane Polymers 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004483 ATR-FTIR spectroscopy Methods 0.000 description 2
- 229920000106 Liquid crystal polymer Polymers 0.000 description 2
- 239000004977 Liquid-crystal polymers (LCPs) Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910020175 SiOH Inorganic materials 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000001393 microlithography Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000005329 nanolithography Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Definitions
- the present invention relates to aptamer coated microneedle based diagnostic skin patches.
- Skin diseases represent a major healthcare challenge in the world today. With over one million skin cancers diagnosed each year in the United States (National Cancer Research Institute, www.cancer.gov), predicting and diagnosing skin diseases is important in terms of their management. Current diagnostic methods rely primarily on visual observation and biopsy. However, detection methods that rely on visual observation are not necessarily effective in diagnosing a skin condition or disease and do not detect risk or disease until clinical signs appear. In addition, invasive methods such as biopsies increase the likelihood of infection as well as trauma to the test subject. In addition, the method must be performed by a physician in order to be safe and usually does not usually provide abundant cell samples on the skin surface, the cells involved in the reaction.
- noninvasive methods of diagnosing and monitoring skin conditions and diseases represent an important means for the care of patients and for evaluating the efficacy of existing and new therapeutics, skin care products and skin care regimens.
- the method can provide important information regarding the genetic predisposition of the test subject to the occurrence of skin disease, as well as specific genetic changes based on the skin condition of the test subject. Identifying these genetic changes can be important in identifying potential drug targets and preventive measures and in determining whether a person actually responds to a particular therapeutic agent, skin care product or regimen.
- detection and diagnostic methods are important for evaluating the safety of such treatments, products, and measures.
- composition of the substance of the skin is changed in various disease states as well as local skin diseases. It is known that various substances such as lipids, structural proteins, inflammatory substances, nucleic acids, and metabolites can be detected in the skin according to the disease state. In addition to atopic dermatitis, melanoma, and bacterial inflammation of the skin, biomarkers are being analyzed for various diseases such as Alzheimer's disease, Parkinson's disease, breast cancer, cardiovascular disease, diabetes, and drug addiction. However, in most cases very invasive skin biopsy is used.
- the present invention has been made in view of the above problems and needs, and an object of the present invention is to provide a patch for use in the diagnosis of various diseases.
- the present invention comprises the steps of: a) binding an amine group to an aptamer; b) attaching a silanol to the surface of the microneedle tip by plasma oxidation, and then adding a hydroxyl; Apylmer-coated microneedle comprising the step of silanizing with 3-glycidoxypropyltrimethoxysilane (3-GPTMS) to a group, and then bonding an amine group bonded to the aptamer to an epoxy group included in the 3-GPTMS. It provides a method for manufacturing a base skin diagnostic patch.
- the present invention is treated with HNO 3 on the surface of the polycarbonate microneedle, and then reduced to NaBH 4 to finally combine the amine group, polyethylene glycol (PEG) is bonded to the carboxyl group at one end and the aptamer at the other end
- PEG polyethylene glycol
- a method for preparing aptamer-coated microneedle-based skin diagnostic patch comprising the step of combining using NHS (N-Hydroxysuccinimide), and EDC [1-ethyl-3- (3'-dimethylaminopropyl) carbodiimide] as a catalyst .
- the present invention also provides an aptamer-coated microneedle-based skin diagnostic patch prepared by the method of the present invention.
- the skin diagnostic patch is characterized in that the aptamer is attached to the microneedle tip surface and the diagnostic component can be attached to the end of the aptamer, but is not limited thereto.
- the diagnostic component is preferably a protein, peptide, DNA or RNA, but is not limited thereto.
- the present invention provides a diagnostic skin that effectively detects various biomarkers present in intracellular interstitial cells by coating a microneedle surface of about 200 um in length that can penetrate the stratum corneum of the skin and lead to epidermis. It's a patch.
- biomarkers that can be collected in the intracellular interstitial tissue are secreted by the infecting bacteria or infectious organisms in various infectious diseases.
- malaria bacteria or proteins released by the bacteria are representative proteins.
- PfHRP2 PfHRP2
- the virus itself can be detected, and in the case of various degenerative brain diseases, for example, the Tau protein is increased in Parkinson's or Alzheimer's disease and can be used as a marker.
- Synuclein can also be used as an important diagnostic marker for Parkinson's disease
- Alymoid beta can be used as a diagnostic marker for Alzheimer's disease
- various cancer markers can be used as a biomarker that can be collected.
- microneedles In connection with the production of aptamer-coated microneedle of the present invention, various types of microneedles have been developed for effective delivery of drugs through brain-machine interfaces (BMIs) or skin and have been tested for measurement of EEG through actual scalp.
- BMIs brain-machine interfaces
- microneedles or microprojection arrays of various materials and lengths are being manufactured.
- the types of chemicals used in the microneedle are as follows. Polyurethane (PU), Polypropylene (PP), Polyethylene (PE), Polystyrene (PS), Poly (methyl methacrylate) (PMMA), Polydimethylsiloxane (PDMS), Polycarbonate (PS), Liquid crystal polymer (LCP).
- An aptamer is a method that detects a specific substance by using a three-dimensional structure of single strand DNA or RNA, which is similar to an antigen-antibody reaction, but because the substance is much smaller, aptamers can be attached to the ends or holes of microneedles. There is an advantage that it can.
- aptamers for various biomarkers can be attached at once (similar to gene chips) to detect multiple kinds of materials at the same time (Multiplexing).
- a gene chip a genome capable of detecting more than 10,000 DNA or RNA can be combined on a nail size chip, so the skin patch can also be used as a biomarker chip by activating a microneedle as an aptamer for various substances.
- a method for detecting a specific substance by using a three-dimensional structure of single strand DNA or RNA called aptamer is similar to an antigen-antibody reaction, but the size of the substance is much smaller and relatively large.
- the advantage is that a large number of aptamers can be bonded to the microneedle tip surface.
- aptamers for various biomarkers can be attached at one time, multiple substances can be detected at the same time (Multiplexing), and microneedle tip-based skin patches can be used as protein chips using aptamers.
- 1 is a structure according to the fabrication of the microneedle and the skin layer using PDMS
- 3 is a method of attaching silanol to the surface of the microneedle tip by plasma oxidation, silanizing the hydroxyl group with 3-GPTMS, and then combining the amine group of PEG coupled with the aptamer to the epoxy group included in 3-GPTMS.
- Figure 5 is a method of coating a polycarbonate microneedle surface with an aptamer bonded to one end of the PEG.
- A After treating HNO3 on the surface of PC microneedle, it is reduced to NaBH4 to finally bind the amine group. Thereafter, PEG, which combines a carboxyl group at one end with an aptamer at the other end, is treated with PC-NH2 along with EDC / NHS to complete the PEG-aptamer functionalized PC microneedle.
- B Identification of NH2-coupled PC via ATR-FTIR.
- C Analysis of the amount of aptamer attached to the surface of the PC using fluorescence tagged anti-sense oligonucleotide.
- the microneedle surface is treated with polyethylene glycol (PEG), and then aptamer is attached to the PEG end to construct the device.
- PEG polyethylene glycol
- Silanol (SiOH) is formed through plasma oxidation of the surface of PDMS constituting the microneedle.
- silanizing this Hydroxyl group with 3-glycidoxypropyltrimethoxysilane (3-GPTMS) having an epoxy group aptamer-PEG can be formed on the surface of the microneedle by combining the amine group (Fig. 4) of PEG with an aptamer combined with this expoxy group. (FIG. 3).
- the surface of the PC microneedle was treated with nitric acid, followed by electrophilic substitution, and reduced nitro groups to prepare PC-NH 2 with primary amine groups.
- the aptamer bound to PEG having a carboxyl group is bound thereto using N-Hydroxysuccinimide (NHS) and 1-ethyl-3- (3′-dimethylaminopropyl) carbodiimide (EDC) as a catalyst (FIG. 5A). That is, HNO3 is treated on the surface of the PC microneedle and then reduced to NaBH4 to finally bind the amine group. Thereafter, PEG, which combines a carboxyl group at one end with an aptamer at the other end, is treated with PC-NH2 along with EDC / NHS to complete the PEG-aptamer functionalized PC microneedle.
- NHS N-Hydroxysuccinimide
- EDC 1-ethyl-3- (3′-dimethylaminopropyl
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to an aptamer-coated microneedle-based diagnostic skin patch, and the patch of the present invention has advantages in that the size of a material is greatly smaller than an antibody material and a large number of aptamers can be bound to tip surfaces of a relatively large number of microneedles. In addition, the patch of the present invention allows the attachment of aptamers for several kinds of biomarkers at the same time, and thus can detect several kinds of materials at the same time (multiplexing), so that a microneedle tip-based skin path can also be used as a protein chip using an aptamer.
Description
본 발명은 앱타머 코팅된 마이크로니들 기반 진단용 피부 패치에 관한 것이다.The present invention relates to aptamer coated microneedle based diagnostic skin patches.
피부 질환은 오늘날 세계에서 주요 건강 관리 도전을 대표한다. 미국(국립암연구소, www.cancer.gov)에서 해마다 새로이 진단되는 백만 건 이상의 피부암과 더불어, 피부 질환을 예측 및 진단하는 것은 그것의 관리 측면에서 중요하다. 현재의 진단 방법은 시각적인 관찰 및 생검에 주로 의존한다. 그러나, 시각적인 관찰에 의존하는 검출 방법은 피부 상태 또는 질환을 진단하는데 반드시 효과적인 것은 아니며, 임상적인 징후가 나타날 때까지 는 위험(risk) 또는 질환을 검출하지 못한다. 게다가, 생검과 같은 침습성 방법은 시험 대상에 대한 외상뿐만 아니라, 감염의 가능성도 증가시킨다. 또한 상기 방법은 안전하게 실시되기 위해서 의사에 의해 수행되어야 하며, 일반적으로 반응에 관여하는 세포인 피부 표면에 있는 풍부한 세포 샘플을 보통 제공하지 않는다.Skin diseases represent a major healthcare challenge in the world today. With over one million skin cancers diagnosed each year in the United States (National Cancer Research Institute, www.cancer.gov), predicting and diagnosing skin diseases is important in terms of their management. Current diagnostic methods rely primarily on visual observation and biopsy. However, detection methods that rely on visual observation are not necessarily effective in diagnosing a skin condition or disease and do not detect risk or disease until clinical signs appear. In addition, invasive methods such as biopsies increase the likelihood of infection as well as trauma to the test subject. In addition, the method must be performed by a physician in order to be safe and usually does not usually provide abundant cell samples on the skin surface, the cells involved in the reaction.
따라서 피부 상태 및 질환을 진단 및 모니터링하는 비침습성 방법은 환자의 관리를 위한, 그리고 기존 및 새로운 치료제, 피부 관리 제품 및 피부 관리 섭생의 효능을 평가하기 위한 중요한 수단을 나타낸다. 게다가, 상기방법은 피부 질환의 발생에 대한 시험 대상의 유전적 소인뿐만 아니라, 시험 대상의 피부 상태를 기초로 하는 특이적인 유전적 변화에 관하여 중요한 정보를 제공할 수 있다. 상기 유전적 변화를 동정하는 것은 잠재적인 약물 타겟 및 예방적 조치를 동정하고 특정 치료제, 피부 관리 제품 또는 섭생에 대해 사람이 실제적으로 반응을 하는지를 결정하는데 중요할 수 있다. 뿐만 아니라, 검출 및 진단 방법은 그러한 치료, 제품 및 조치의 안전성을 평가하는데 중요하다.Thus, noninvasive methods of diagnosing and monitoring skin conditions and diseases represent an important means for the care of patients and for evaluating the efficacy of existing and new therapeutics, skin care products and skin care regimens. In addition, the method can provide important information regarding the genetic predisposition of the test subject to the occurrence of skin disease, as well as specific genetic changes based on the skin condition of the test subject. Identifying these genetic changes can be important in identifying potential drug targets and preventive measures and in determining whether a person actually responds to a particular therapeutic agent, skin care product or regimen. In addition, detection and diagnostic methods are important for evaluating the safety of such treatments, products, and measures.
또한, 국소적인 피부질환은 물론 다양한 질병상태에서 피부의 물질의 조성이 바뀌는 것이 보고되고 있다. 지질, 구조단백질, 염증성물질, 핵산, 대사산물 등 여러물질이 질병상태에 따라 피부에서 다양하게 검출되는 것으로 알려져있다. 현재 아토피성 피부염, 흑색종, 피부의 세균성 염증 외에도 알츠하이머병, 파킨슨씨병, 유방암, 심혈관계 질환, 당뇨병, 약물 중독등의 다양한 질환에서 피부의 바이오마커 분석이 이루어지고 있다. 그러나, 대부분의 경우 대단히 침습적인 피부생검(Skin Biopsy)이 사용되고 있다. 비침습적 방법으로 Iontophoresis, Microdialysis, Tape stripping, Ultrasound, Microneedle등이 사용되고 있으나, 매우 효율은 낮은 편이다 (Paliwal et al., 2013 Diagnostic opportunities based on skin biomarkers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 50:546-556). In addition, it has been reported that the composition of the substance of the skin is changed in various disease states as well as local skin diseases. It is known that various substances such as lipids, structural proteins, inflammatory substances, nucleic acids, and metabolites can be detected in the skin according to the disease state. In addition to atopic dermatitis, melanoma, and bacterial inflammation of the skin, biomarkers are being analyzed for various diseases such as Alzheimer's disease, Parkinson's disease, breast cancer, cardiovascular disease, diabetes, and drug addiction. However, in most cases very invasive skin biopsy is used. Iontophoresis, Microdialysis, Tape stripping, Ultrasound, Microneedle are used as non-invasive methods, but the efficiency is low (Paliwal et al., 2013 Diagnostic opportunities based on skin biomarkers.European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 50: 546-556.
[선행 특허 문헌][Previous Patent Document]
대한민국 특허공개번호 제1020120006945호Republic of Korea Patent Publication No. 1020120006945
본 발명은 상기의 문제점을 해결하고 필요성에 의하여 안출된 것으로서 본 발명의 목적은 다양한 질환의 진단에 이용하기 위한 패치를 제공하는 것이다. SUMMARY OF THE INVENTION The present invention has been made in view of the above problems and needs, and an object of the present invention is to provide a patch for use in the diagnosis of various diseases.
상기의 목적을 달성하기 위하여 본 발명은 a) 앱타머에 아민기를 결합시키는 단계;b) 마이크로니들 팁 표면을 프라즈마 산화(plasma oxidation)로 실라놀(silanol)을 붙인 후, 그 하이드록실(hydroxyl)기에 3-glycidoxypropyltrimethoxysilane (3-GPTMS)으로 실란처리(silanizing)한 후, 상기 3-GPTMS에 포함된 에폭시(epoxy)기에 상기 앱타머에 결합된 아민기를 결합시키는 단계를 포함하는 앱타머가 코팅된 마이크로니들 기반 피부 진단 패치 제조방법을 제공한다.In order to achieve the above object, the present invention comprises the steps of: a) binding an amine group to an aptamer; b) attaching a silanol to the surface of the microneedle tip by plasma oxidation, and then adding a hydroxyl; Apylmer-coated microneedle comprising the step of silanizing with 3-glycidoxypropyltrimethoxysilane (3-GPTMS) to a group, and then bonding an amine group bonded to the aptamer to an epoxy group included in the 3-GPTMS. It provides a method for manufacturing a base skin diagnostic patch.
또 본 발명은 폴리카보네이트(Polycarbonate) 마이크로니들 표면에 HNO3를 처리한 후 NaBH4로 환원시켜서 최종적으로 아민기를 결합시킨 후 한쪽 끝에 카르복실기를 다른 한쪽 끝에 앱타머와 결합하고 있는 폴리에틸렌글리콜(PEG)을 NHS(N-Hydroxysuccinimide), 및 EDC[1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide]를 촉매로 사용하여 결합시키는 단계를 포함하는 앱타머가 코팅된 마이크로니들 기반 피부 진단 패치 제조방법을 제공한다.In addition, the present invention is treated with HNO 3 on the surface of the polycarbonate microneedle, and then reduced to NaBH 4 to finally combine the amine group, polyethylene glycol (PEG) is bonded to the carboxyl group at one end and the aptamer at the other end Provides a method for preparing aptamer-coated microneedle-based skin diagnostic patch comprising the step of combining using NHS (N-Hydroxysuccinimide), and EDC [1-ethyl-3- (3'-dimethylaminopropyl) carbodiimide] as a catalyst .
또 본 발명은 상기 본 발명의 방법에 의하여 제조된 앱타머가 코팅된 마이크로니들 기반 피부 진단 패치를 제공한다.The present invention also provides an aptamer-coated microneedle-based skin diagnostic patch prepared by the method of the present invention.
본 발명의 일 구현예에 있어서, 상기 피부 진단 패치는 마이크로니들 팁 표면에 앱타머가 부착되고 상기 앱타머의 말단에는 진단 가능한 성분이 부착될 수 있는 것을 특징으로 하나 이에 한정되지 아니한다. 상기 진단 가능한 성분은 단백질, 펩타이드, DNA 또는 RNA인 것이 바람직하나 이에 한정되지 아니한다.In one embodiment of the present invention, the skin diagnostic patch is characterized in that the aptamer is attached to the microneedle tip surface and the diagnostic component can be attached to the end of the aptamer, but is not limited thereto. The diagnostic component is preferably a protein, peptide, DNA or RNA, but is not limited thereto.
이하 본 발명을 설명한다.Hereinafter, the present invention will be described.
본 발명은 피부의 각질층 (stratum corneum) 을 침투하여 표피증에 이를 수 있는 길이 약 200 um의 microneedle 표면을 앱타머로 코팅하여 피부내 세포간질에 존재하는 다양한 바이오마커를 효과적으로 검출할 수 있게 한 진단용 스킨패치이다.The present invention provides a diagnostic skin that effectively detects various biomarkers present in intracellular interstitial cells by coating a microneedle surface of about 200 um in length that can penetrate the stratum corneum of the skin and lead to epidermis. It's a patch.
피부내 세포간질에 포함되어 포집이 가능한 바이오마커의 종류는 각종 감염성 진환에서 감염균 자체나 감염균이 분비하는 물질로, 예를 들면, 말라리아의 경우, 말라리아 균 자체나 균이 배출하는 단백질 등이고, 대표적인 단백질이 PfHRP2이며, 각종 바이러스의 경우 그 바이러스 자체를 검출할 수 있으며, 또한, 각종 퇴행성 뇌질환의 경우, 예를 들어, Tau 단백질은 파킨슨씨 혹은 알츠하이머씨 병에서 증가되어 마커로 사용할 수 있으며, Alpha-synuclein도 파킨슨씨 병의 중요한 진단 마커로 사용될 수 있고, Alymoid beta도 알츠하이머씨 병의 진단 마커로 사용될 수 있고, 또한 각종 암표지자도 포집가능한 바이오마커로 사용될 수 있다.The types of biomarkers that can be collected in the intracellular interstitial tissue are secreted by the infecting bacteria or infectious organisms in various infectious diseases. For example, in case of malaria, malaria bacteria or proteins released by the bacteria are representative proteins. This is PfHRP2, and in the case of various viruses, the virus itself can be detected, and in the case of various degenerative brain diseases, for example, the Tau protein is increased in Parkinson's or Alzheimer's disease and can be used as a marker. Synuclein can also be used as an important diagnostic marker for Parkinson's disease, Alymoid beta can be used as a diagnostic marker for Alzheimer's disease, and various cancer markers can be used as a biomarker that can be collected.
본 발명의 앱타머가 코팅된 마이크로니들 제작과 관련하여서는 Brain-machine interfaces (BMIs)나 피부를 통한 효과적인 약물의 delivery를 위해 그간 여러 종류의 microneedle이 개발되었고 실제 두피를 통한 뇌파의 측정등에 테스트 되었다.In connection with the production of aptamer-coated microneedle of the present invention, various types of microneedles have been developed for effective delivery of drugs through brain-machine interfaces (BMIs) or skin and have been tested for measurement of EEG through actual scalp.
한 예로 2011년에 발표된 Ami, Y et al, J of Micro/Nanolithography, MEMS, and MOEMS. 10 (1), 011503, March 2011 논문을 참고하면Polydimethylsiloxane (PDMS)를 재료로 두께 50 um x 길이 200 um로 끝이 뾰족한 스킨침투용 마이크로니들을 성공적으로 개발한 것을 볼 수 있다.(도 1).For example, Ami, Y et al, J of Micro / Nanolithography, MEMS, and MOEMS, published in 2011. 10 (1), 011503, March 2011 It can be seen that the successful development of the skin penetrating microneedle with a pointed tip with a thickness of 50 um x 200 um in length using polydimethylsiloxane (PDMS) (FIG. 1). .
그외 다양한 소재와 길이의 마이크로니들 (microneedle 혹은 microprojection array) 이 제작되고 있다. 마이크로니들의 소재로 쓰이는 화학물질의 종류는 다음과 같다. Polyurethane (PU), Polypropylene (PP), Polyethylene (PE), Polystyrene (PS), Poly(methyl methacrylate) (PMMA), Polydimethylsiloxane (PDMS), Polycarbonate (PS), Liquid crystal polymer (LCP).In addition, microneedles or microprojection arrays of various materials and lengths are being manufactured. The types of chemicals used in the microneedle are as follows. Polyurethane (PU), Polypropylene (PP), Polyethylene (PE), Polystyrene (PS), Poly (methyl methacrylate) (PMMA), Polydimethylsiloxane (PDMS), Polycarbonate (PS), Liquid crystal polymer (LCP).
앱타머란 single strand DNA나 RNA의 삼차원구조를 이용해 특정 물질을 검출하는 방법으로 항원-항체 반응과 비슷하나 물질의 사이즈가 훨씬 작아서 마이크로니들의 끝이나 내부의 홀에 많은 수의 앱타머를 결합시킬 수 있다는 장점이 있다. An aptamer is a method that detects a specific substance by using a three-dimensional structure of single strand DNA or RNA, which is similar to an antigen-antibody reaction, but because the substance is much smaller, aptamers can be attached to the ends or holes of microneedles. There is an advantage that it can.
또한 여러 종류의 바이오 마커에 대한 앱타머를 한꺼번에 붙일 수 있으므로 (유전자칩과 비슷한 개념) 동시에 여러 종류의 물질을 검출할 수 있다 (Multiplexing). 유전자 칩의 경우 손톱크기의 칩 위에 10,000종류 이상의 DNA나 RNA를 검출할 수 있는 유전체를 결합시킬 수 있으므로, 이론적으로 스킨패치도 다양한 물질에 대한 앱타머로 microneedle을 활성화하여 바이오마커칩으로 사용할 수 있다.In addition, aptamers for various biomarkers can be attached at once (similar to gene chips) to detect multiple kinds of materials at the same time (Multiplexing). In the case of a gene chip, a genome capable of detecting more than 10,000 DNA or RNA can be combined on a nail size chip, so the skin patch can also be used as a biomarker chip by activating a microneedle as an aptamer for various substances.
앱타머를 이용한 피부 진단 패치의 개발의 경우 표피층의 세포간질에 존재하는 바이오마커를 detection해야 하므로 약 20 um 의 각질층을 통과해야 하는 문제점이 있다. 이 문제를 마이크로니들을 통해 해결한 진단용 스킨 패치 제작을 위해 다음과 같이 앱타머를 마이크로니들에 붙일 수 있다.In the development of a skin diagnostic patch using aptamers, biomarkers present in the epilepsy of the epidermal layer need to be detected. To create a diagnostic skin patch that solves this problem with a microneedle, you can attach an aptamer to the microneedle as follows:
본 발명을 통하여 알 수 있는 바와 같이, 본 발명에서 앱타머라는 single strand DNA나 RNA의 삼차원구조를 이용해 특정 물질을 검출하는 방법으로 항원-항체 반응과 비슷하나 물질의 사이즈가 훨씬 작고 상대적으로 많은 수의 마이크로니들 팁 표면에 많은 수의 앱타머를 결합시킬 수 있다는 장점이 있다. As can be seen through the present invention, in the present invention, a method for detecting a specific substance by using a three-dimensional structure of single strand DNA or RNA called aptamer is similar to an antigen-antibody reaction, but the size of the substance is much smaller and relatively large. The advantage is that a large number of aptamers can be bonded to the microneedle tip surface.
또한 여러 종류의 바이오 마커에 대한 앱타머를 한꺼번에 붙일 수 있으므로 동시에 여러 종류의 물질을 검출할 수 있어서(Multiplexing), 마이크로니들 팁 기반 스킨패치도 앱타머를 이용한 단백질 칩으로 사용할 수 있다.In addition, since aptamers for various biomarkers can be attached at one time, multiple substances can be detected at the same time (Multiplexing), and microneedle tip-based skin patches can be used as protein chips using aptamers.
도 1은 PDMS를 이용한 microneedle의 제작과 피부의 층에 맞추어 본 구조,1 is a structure according to the fabrication of the microneedle and the skin layer using PDMS,
도 2는 마이크로니들과 이를 이용한 패치 예,2 is a microneedle and an example patch using the same;
도 3은 Microneedle tip 표면을 plasma oxidation 으로 silanol을 붙인후, hydroxyl 기에 3-GPTMS로 silanizing후 3-GPTMS에 포함된epoxy기에 앱타머와 결합된 PEG의 amine 기를 결합시키는 방법,3 is a method of attaching silanol to the surface of the microneedle tip by plasma oxidation, silanizing the hydroxyl group with 3-GPTMS, and then combining the amine group of PEG coupled with the aptamer to the epoxy group included in 3-GPTMS.
도 4는 Amine (NH2-)기가 결합된 PEG에 연결된 앱타머,4 shows aptamers linked to PEG with Amine (NH2-) groups bound,
도 5는 Polycarbonate microneedle표면을 PEG의 한쪽 끝에 결합한 앱타머로 코팅하는 방법. (A) PC microneedle 표면에 HNO3를 처리한 후 NaBH4로 환원시켜서 최종적으로 amine group을 결합시킨다. 이후 한쪽 끝에 carboxyl group을, 다른 한쪽 끝에 앱타머와 결합하고 있는 PEG을 EDC/NHS와 함께 PC-NH2에 처리하여 완성된 PEG-aptamer functionalized된 PC microneedle을 완성시킨다. (B) ATR-FTIR을 통해 NH2-가 결합된 PC를 확인. (C) Fluorescence tagged anti-sense oligonucleotide를 이용해 PC표면에 부착된 aptamer의 양을 분석함.Figure 5 is a method of coating a polycarbonate microneedle surface with an aptamer bonded to one end of the PEG. (A) After treating HNO3 on the surface of PC microneedle, it is reduced to NaBH4 to finally bind the amine group. Thereafter, PEG, which combines a carboxyl group at one end with an aptamer at the other end, is treated with PC-NH2 along with EDC / NHS to complete the PEG-aptamer functionalized PC microneedle. (B) Identification of NH2-coupled PC via ATR-FTIR. (C) Analysis of the amount of aptamer attached to the surface of the PC using fluorescence tagged anti-sense oligonucleotide.
도 6은 PEG-aptamer로 표면이 코팅된 PC microneedle.6 is a PC microneedle surface coated with PEG-aptamer.
이하 비한정적인 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 단 하기 실시예는 본 발명을 예시하기 위한 의도로 기재한 것으로서 본 발명의 범위는 하기 실시예에 의하여 제한되는 것으로 해석되지 아니한다. Hereinafter, the present invention will be described in more detail with reference to non-limiting examples. However, the following examples are intended to illustrate the present invention and the scope of the present invention is not to be construed as limited by the following examples.
실시예Example
1:Microneedle1: Microneedle
tip 표면에 on the tip surface
앱타머를Aptamer
부착시키는 Attached
반응예Example of reaction
마이크로니들에 비특이적으로 결합하는 단백질로 인한 진단의 부정확성을 피하기 위하여, 마이크로니들 표면을 polyethylene glycol(PEG)로 처리한 후 aptamer를 PEG끝에 부착하여 기기를 구성한다.In order to avoid inaccuracy of diagnosis due to proteins that bind nonspecifically to the microneedle, the microneedle surface is treated with polyethylene glycol (PEG), and then aptamer is attached to the PEG end to construct the device.
A. A.
PDMSPDMS
microneedle의microneedle
예:Yes:
Microneedle을 구성하는 PDMS의 표면을 Plasma oxidation을 통해 Silanol (SiOH)을 형성한다. 이 Hydroxyl 기를 epoxy기를 가지고 있는 3-glycidoxypropyltrimethoxysilane (3-GPTMS) 로 silanizing 후 이 expoxy기에 앱타머와 결합된 PEG의 amine기 (도 4) 를 결합함으로서 Microneedle의 표면에 앱타머-PEG을 구성할 수 있다 (도 3).Silanol (SiOH) is formed through plasma oxidation of the surface of PDMS constituting the microneedle. By silanizing this Hydroxyl group with 3-glycidoxypropyltrimethoxysilane (3-GPTMS) having an epoxy group, aptamer-PEG can be formed on the surface of the microneedle by combining the amine group (Fig. 4) of PEG with an aptamer combined with this expoxy group. (FIG. 3).
B.B.
PolycarbonatePolycarbonate
microneedle표면을microneedle surface
PEG의 한쪽 끝에 결합한 Bound to one end of the PEG
앱타머로With aptamer
코팅하는 방법: How to coat:
PC 마이크로니들의 표면을 nitric acid 처리로 electrophilic substitution 후 nitro groups을 환원시켜서 primary amine group 을 붙여 PC-NH2를 준비한다. 여기에 carboxyl 기를 갖는 PEG에 결합된 앱타머를 N-Hydroxysuccinimide (NHS), 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide (EDC)를 촉매로 사용하여 결합시킨다 (도. 5A). 즉, PC microneedle 표면에 HNO3를 처리한 후 NaBH4로 환원시켜서 최종적으로 amine group을 결합시킨다. 이후 한쪽 끝에 carboxyl group을, 다른 한쪽 끝에 앱타머와 결합하고 있는 PEG을 EDC/NHS와 함께 PC-NH2에 처리하여 완성된 PEG-aptamer functionalized된 PC microneedle을 완성시킨다.The surface of the PC microneedle was treated with nitric acid, followed by electrophilic substitution, and reduced nitro groups to prepare PC-NH 2 with primary amine groups. The aptamer bound to PEG having a carboxyl group is bound thereto using N-Hydroxysuccinimide (NHS) and 1-ethyl-3- (3′-dimethylaminopropyl) carbodiimide (EDC) as a catalyst (FIG. 5A). That is, HNO3 is treated on the surface of the PC microneedle and then reduced to NaBH4 to finally bind the amine group. Thereafter, PEG, which combines a carboxyl group at one end with an aptamer at the other end, is treated with PC-NH2 along with EDC / NHS to complete the PEG-aptamer functionalized PC microneedle.
Polycarbonate에 amine기의 결합은ATR- FTIR 방법을 통해 확인하였고 (도 5B), 두번째 반응에 의한PEG에 결합된 앱타머의 결합은 fluorescence tagged oligonucleotide를 이용한 방법을 통해 증명하였다 (도 5C).The binding of amine groups to polycarbonate was confirmed by the ATR-FTIR method (FIG. 5B), and the binding of aptamers bound to PEG by the second reaction was demonstrated by the method using fluorescence tagged oligonucleotide (FIG. 5C).
상기의 두 단계 반응을 통해 도 6에서 보여주는 것과 같은 polycarbonate microneedle의 표면을 PEG에 부착된 앱타머로 코팅한 피부의 바이오마커 진단용 스킨패치를 구축하였다.Through the two-step reaction described above, a skin patch for diagnosing a biomarker of the skin coated with aptamer attached to PEG was coated on the surface of the polycarbonate microneedle as shown in FIG. 6.
Claims (5)
- a) 앱타머에 아민기를 결합시키는 단계;b) 마이크로니들 팁 표면을 프라즈마 산화(plasma oxidation)로 실라놀(silanol)을 붙인 후, 그 하이드록실(hydroxyl)기에 3-glycidoxypropyltrimethoxysilane (3-GPTMS)으로 실란처리(silanizing)한 후, 상기 3-GPTMS에 포함된 에폭시(epoxy)기에 상기 앱타머에 결합된 아민기를 결합시키는 단계를 포함하는 앱타머가 코팅된 마이크로니들 기반 피부 진단 패치 제조방법.a) binding an amine group to an aptamer; b) attaching a silanol to the surface of the microneedle tip with plasma oxidation, followed by 3-glycidoxypropyltrimethoxysilane (3-GPTMS) to the hydroxyl group. After silane treatment (silanizing), a method for producing a microneedle-based skin diagnostic patch coated with an aptamer comprising the step of bonding an amine group bonded to the aptamer to an epoxy group contained in the 3-GPTMS.
- 폴리카보네이트(Polycarbonate) 마이크로니들 표면에 HNO3를 처리한 후 NaBH4로 환원시켜서 최종적으로 아민기를 결합시킨 후 한쪽 끝에 카르복실기를 다른 한쪽 끝에 앱타머와 결합하고 있는 폴리에틸렌글리콜(PEG)을 NHS(N-Hydroxysuccinimide), 및 EDC[1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide]를 촉매로 사용하여 결합시키는 단계를 포함하는 앱타머가 코팅된 마이크로니들 기반 피부 진단 패치 제조방법.After treating HNO 3 on the surface of polycarbonate microneedle, reducing it to NaBH 4 to finally combine the amine group, polyethylene glycol (PEG), which combines a carboxyl group with an aptamer at one end, is NHS (N- Hydroxysuccinimide), and a method for producing aptamer-coated microneedle-based skin diagnostic patch comprising the step of binding using EDC [1-ethyl-3- (3'-dimethylaminopropyl) carbodiimide] as a catalyst.
- 제1항 또는 제2항의 방법에 의하여 제조된 앱타머가 코팅된 마이크로니들 기반 피부 진단 패치.An aptamer-coated microneedle based skin diagnostic patch prepared by the method of claim 1.
- 제3항에 있어서, 상기 피부 진단 패치는 마이크로니들 팁 표면에 앱타머가 부착되고 상기 앱타머의 말단에는 진단 가능한 성분이 부착될 수 있는 것을 특징으로 하는 마이크로니들 기반 피부 진단 패치. 4. The microneedle-based skin diagnostic patch of claim 3, wherein the skin diagnostic patch has an aptamer attached to the surface of the microneedle tip and a diagnostic component can be attached to the end of the aptamer.
- 제4항에 있어서, 상기 진단 가능한 성분은 단백질, 펩타이드, DNA 또는 RNA인 것을 특징으로 하는 마이크로니들 기반 피부 진단 패치. 5. The microneedle based skin diagnostic patch of claim 4, wherein the diagnosable component is a protein, peptide, DNA or RNA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0097854 | 2015-07-09 | ||
| KR20150097854 | 2015-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017007271A1 true WO2017007271A1 (en) | 2017-01-12 |
Family
ID=57685840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2016/007410 WO2017007271A1 (en) | 2015-07-09 | 2016-07-08 | Aptamer-coated microneedle-based diagnostic skin patch |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2017007271A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018124327A1 (en) * | 2016-12-28 | 2018-07-05 | 주식회사 넥스모스 | Method for fabricating microneedle-based diagnostic skin patch coated with aptamer and patch |
| CN115397309A (en) * | 2020-04-07 | 2022-11-25 | 株式会社乐派司 | Minimally invasive atopic dermatitis examination method using microneedle patch and minimally invasive atopic examination kit including microneedle patch |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020081597A1 (en) * | 2000-03-31 | 2002-06-27 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| US20110160069A1 (en) * | 2008-05-23 | 2011-06-30 | The University Of Queensland | Analyte detection using a needle projection patch |
| KR20130060009A (en) * | 2011-11-29 | 2013-06-07 | 삼성전자주식회사 | Device for detecting and separating target biomolecules and method for detecting and separating target biomolecules using the same |
| US20140287942A1 (en) * | 2012-12-14 | 2014-09-25 | The Scripps Research Institute | Methods and Devices for Detection and Acquisition of Biomarkers |
| KR101502204B1 (en) * | 2012-01-27 | 2015-03-13 | 경희대학교 산학협력단 | Method for detecting and quantifying target proteins |
-
2016
- 2016-07-08 WO PCT/KR2016/007410 patent/WO2017007271A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020081597A1 (en) * | 2000-03-31 | 2002-06-27 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| US20110160069A1 (en) * | 2008-05-23 | 2011-06-30 | The University Of Queensland | Analyte detection using a needle projection patch |
| KR20130060009A (en) * | 2011-11-29 | 2013-06-07 | 삼성전자주식회사 | Device for detecting and separating target biomolecules and method for detecting and separating target biomolecules using the same |
| KR101502204B1 (en) * | 2012-01-27 | 2015-03-13 | 경희대학교 산학협력단 | Method for detecting and quantifying target proteins |
| US20140287942A1 (en) * | 2012-12-14 | 2014-09-25 | The Scripps Research Institute | Methods and Devices for Detection and Acquisition of Biomarkers |
Non-Patent Citations (1)
| Title |
|---|
| KAMRA, T. ET AL.: "Covalent Immobilization of Molecularly Imprinted Polymer Nanoparticles Using an Epoxy Silane", JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 445, 7 January 2015 (2015-01-07), pages 277 - 284, XP029165030 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018124327A1 (en) * | 2016-12-28 | 2018-07-05 | 주식회사 넥스모스 | Method for fabricating microneedle-based diagnostic skin patch coated with aptamer and patch |
| CN115397309A (en) * | 2020-04-07 | 2022-11-25 | 株式会社乐派司 | Minimally invasive atopic dermatitis examination method using microneedle patch and minimally invasive atopic examination kit including microneedle patch |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018124327A1 (en) | Method for fabricating microneedle-based diagnostic skin patch coated with aptamer and patch | |
| Al Sulaiman et al. | Hydrogel-coated microneedle arrays for minimally invasive sampling and sensing of specific circulating nucleic acids from skin interstitial fluid | |
| Madden et al. | Biosensing in dermal interstitial fluid using microneedle based electrochemical devices | |
| Babity et al. | Advances in the design of transdermal microneedles for diagnostic and monitoring applications | |
| US20210338158A1 (en) | Measurement system | |
| Romanyuk et al. | Collection of analytes from microneedle patches | |
| Yang et al. | In situ sampling and monitoring cell-free DNA of the Epstein–Barr virus from dermal interstitial fluid using wearable microneedle patches | |
| Dixon et al. | Microneedle-based devices for point-of-care infectious disease diagnostics | |
| Zhao et al. | Nanoelectronic coating enabled versatile multifunctional neural probes | |
| Wang et al. | Microneedle-based transdermal detection and sensing devices | |
| AU2019352635B2 (en) | Actuator system | |
| Coffey et al. | Rapid and selective sampling of IgG from skin in less than 1 min using a high surface area wearable immunoassay patch | |
| US20210386373A1 (en) | Analyte detection system | |
| US20210402182A1 (en) | Treatment delivery system | |
| Li et al. | Interstitial fluid biomarkers’ minimally invasive monitoring using microneedle sensor arrays | |
| JP2022508576A (en) | Electrode equipment | |
| Chang et al. | Wearable devices for single-cell sensing and transfection | |
| Park et al. | Hydrogel microneedles extracting exosomes for early detection of colorectal cancer | |
| WO2017007271A1 (en) | Aptamer-coated microneedle-based diagnostic skin patch | |
| Yang et al. | A swellable bilateral microneedle patch with core-shell structure for rapid lactate analysis and early melanoma diagnosis | |
| Poudineh | Microneedle Assays for Continuous Health Monitoring: Challenges and Solutions | |
| KR20170041375A (en) | A Microneedle skin patch functionalized by Aptamer-coated carbon nanotube for early diagnosis of various diseases | |
| US20200054256A1 (en) | Method for fabricating microneedle-based diagnostic skin patch coated with aptamer and patch | |
| US20220346679A1 (en) | Analyte measurement system | |
| WO2020235697A1 (en) | Improved method for manufacturing microneedle-based diagnostic skin patch coated with aptamer, and patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16821677 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/04/2018) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16821677 Country of ref document: EP Kind code of ref document: A1 |